CoMentis Company
AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
%20.jpg)
Last Funding Type:
Series E
Investment Stage:
N/A
Funding Status:
Late Stage Venture
Headquarters:
United States
Industry:
Regenerative medicine
Number Of Exists:
N/A
Investor Type:
N/A
Technology:
Stem Cell
Total Funding:
$107.5M
Investors Number:
14
Employee Number:
51-100
Founded Date:
2004